Royalty Pharma RPRX Share Repurchase Program - Amount Remaining
Share Repurchase Program - Amount Remaining at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
In January 2025, our board of directors authorized a share repurchase program under which we may repurchase up to $3.0 billion of our Class A ordinary shares. The repurchases may be made in the open market or in privately negotiated transactions. The share repurchase program has been approved by our board of directors through June 2027 and shareholders have approved the terms of our share repurchase contracts and counterparties thereto through June 2031. In the first six months of 2026, we repurchased 2.0 million shares at a cost of approximately $95.6 million. As of June 30, 2026, approximately $1.7 billion remained available under the share repurchase program.
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's share repurchase program - amount remaining?
- Royalty Pharma (RPRX) reported share repurchase program - amount remaining of $1.7B in Q2 2026.
- How has Royalty Pharma's share repurchase program - amount remaining changed year-over-year?
- Royalty Pharma's share repurchase program - amount remaining decreased by 15.0% year-over-year, from $2B to $1.7B.
- What does share repurchase program - amount remaining mean?
- The remaining dollar amount authorized by the board of directors for the repurchase of common stock.
Ask your AI about Royalty Pharma's share repurchase program - amount remaining.
Connect your AI assistant and compare it to peers, right in your chat.
